A Study to Examine the Safety, Tolerability, and Pharmacokinetics of Single- and Multiple-ascending Doses of ACT-777991 in Healthy Subjects
A Single-center, Double-blind, Randomized, Placebo-controlled Phase 1 Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Single- and Multiple-ascending Doses of ACT-777991 in Healthy Subjects
Sponsor: Idorsia Pharmaceuticals Ltd.
This PHASE1 trial investigates Healthy and is currently completed. Idorsia Pharmaceuticals Ltd. leads this study, which shows 6 recorded versions since 2021 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Jul 2022 — Jul 2024 [monthly]
Completed PHASE1
Status: Active Not Recruiting → Completed
-
Jun 2022 — Jul 2022 [monthly]
Active Not Recruiting PHASE1
-
Mar 2022 — Jun 2022 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
▶ Show 1 earlier version
-
Apr 2021 — Mar 2022 [monthly]
Recruiting PHASE1
First recorded
Jan 2021
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Idorsia Pharmaceuticals Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .